Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention

• Main Authors: Nicolas Lecrenier (Author), Pierre Beukelaers (Author), Romulo Colindres (Author), Desmond Curran (Author), Carine De Kesel (Author), Jean-Philippe De Saegher (Author), Arnaud M Didierlaurent (Author), Edouard Y Ledent (Author), Johann F Mols (Author), Tomas Mrkvan (Author), Marie Normand-Bayle (Author), Lidia Oostvogels (Author), Fernanda Tavares Da Silva (Author), Ventzislav Vassilev (Author), Carlota Vinals (Author), Alain Brecx (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: GSK has developed a two-dose adjuvanted recombinant zoster vaccine (Shingrix, RZV) to protect people aged ≥50 years (50+) against herpes zoster (HZ) and its complications. RZV showed >90% efficacy against HZ, sustained over 4 years of follow-up, in all studied age groups. Areas cove...